Cite
HARVARD Citation
van der Heijde, D. et al. (2020). Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study. Annals of the rheumatic diseases. 79 (5), pp. 595-604. [Online].